(T 18) Treatment outcomes with rimegepant versus other standard of care acute migraine medications in the observational CONFIDENCE study

Presenting Author(s)

Peter Goadsby, PhD DSc FRACP FRCP FMedSci FRS

Professor of Neurology and Honorary Consultant Neurologist
University of Leeds UK, King Abdullah University of Science and Technology, Saudi Arabia,NIHR King’s Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
London, United Kingdom

Richard B. Lipton, MD

Edwin S. Lowe Professor and Vice Chair of Neurology; Director, Montefiore Headache Center
Montefiore Medical Center and the Albert Einstein College of Medicine
Bronx, NY, United States
LA

Lucy Abraham, n/a

Senior Director, HVE Team Lead, Migraine
Pfizer R&D UK Ltd.,Tadworth, Surrey, UK
Tadworth, England, United States
AU

Alexandre Urani, n/a

Aptar Digital Health, Paris, France
Paris, Ile-de-France, United States
GL

Giorgio Lambru, n/a

The Headache and Facial Pain Service, Guy's and St. Thomas' NHS Foundation Trust, London, UK, United States
PP

Patricia Pozo-Rosich, n/a

Headache Unit, Neurology Department, Vall d'Hebron Hospital, and Headache Research Group, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
Barcelona, Catalonia, United States
KF

Kristina M. Fanning, PhD

Principal Owner
MIST Research & Statistical Consulting
Wilmington, North Carolina, United States